首页 > 最新文献

Critical Care Explorations最新文献

英文 中文
Epic Sepsis Model Inpatient Predictive Analytic Tool: A Validation Study. Epic败血症模型住院患者预测分析工具:一项验证研究。
Pub Date : 2023-07-01 DOI: 10.1097/CCE.0000000000000941
John Cull, Robert Brevetta, Jeff Gerac, Shanu Kothari, Dawn Blackhurst

Earlier treatment of sepsis leads to decreased mortality. Epic is an electronic medical record providing a predictive alert system for sepsis, the Epic Sepsis Model (ESM) Inpatient Predictive Analytic Tool. External validation of this system is lacking. This study aims to evaluate the ESM as a sepsis screening tool and determine whether an association exists between ESM alert system implementation and subsequent sepsis-related mortality.

Design: Before-and-after study comparing baseline and intervention period.

Setting: Urban 746-bed academic level 1 trauma center.

Patients: Adult acute care inpatients discharged between January 12, 2018, and July 31, 2019.

Interventions: During the before period, ESM was turned on in the background, but nurses and providers were not alerted of results. The system was then activated to alert providers of scores greater than or equal to 5, a set point determined using receiver operating characteristic curve analysis (area under the curve, 0.834; p < 0.001).

Measurements and main results: Primary outcome was mortality during hospitalization; secondary outcomes were sepsis order set utilization, length of stay, and timing of administration of sepsis-appropriate antibiotics. Of the 11,512 inpatient encounters assessed by ESM, 10.2% (1,171) had sepsis based on diagnosis codes. As a screening test, the ESM had sensitivity, specificity, positive predictive value, and negative predictive value rates of 86.0%, 80.8%, 33.8%, and 98.11%, respectively. After ESM implementation, unadjusted mortality rates in patients with ESM score greater than or equal to 5 and who had not yet received sepsis-appropriate antibiotics declined from 24.3% to 15.9%; multivariable analysis yielded an odds ratio of sepsis-related mortality (95% CI) of 0.56 (0.39-0.80).

Conclusions: In this single-center before-and-after study, utilization of the ESM score as a screening test was associated with a 44% reduction in the odds of sepsis-related mortality. Due to wide utilization of Epic, this is a potentially promising tool to improve sepsis mortality in the United States. This study is hypothesis generating, and further work with more rigorous study design is needed.

早期治疗败血症可降低死亡率。Epic是一种电子病历,提供败血症的预测警报系统,即Epic败血症模型(ESM)住院患者预测分析工具。该系统缺乏外部验证。本研究旨在评估ESM作为败血症筛查工具的作用,并确定ESM警报系统的实施与随后败血症相关死亡率之间是否存在关联。设计:前后比较基线和干预期的研究。环境:城市746个床位的一级创伤中心。患者:2018年1月12日至2019年7月31日出院的成人急症住院患者。干预措施:在术前,ESM在后台打开,但护士和提供者没有被告知结果。然后激活系统,提醒提供者分数大于或等于5,这是一个设定值,由受试者工作特征曲线分析确定(曲线下面积,0.834;P < 0.001)。测量方法和主要结果:主要结局为住院期间死亡率;次要结果是脓毒症的使用顺序、住院时间和使用适合脓毒症的抗生素的时间。在ESM评估的11,512例住院患者中,根据诊断代码,10.2%(1,171例)患有败血症。作为筛查试验,ESM的敏感性、特异性、阳性预测值和阴性预测值分别为86.0%、80.8%、33.8%和98.11%。实施ESM后,ESM评分大于或等于5且尚未接受败血症适宜抗生素治疗的患者的未调整死亡率从24.3%下降到15.9%;多变量分析得出败血症相关死亡率的比值比(95% CI)为0.56(0.39-0.80)。结论:在这项单中心前后对照研究中,使用ESM评分作为筛选试验与败血症相关死亡率降低44%相关。由于Epic的广泛应用,这是一个潜在的有前途的工具,以提高败血症死亡率在美国。本研究是假设生成的,需要进一步开展更严格的研究设计。
{"title":"Epic Sepsis Model Inpatient Predictive Analytic Tool: A Validation Study.","authors":"John Cull,&nbsp;Robert Brevetta,&nbsp;Jeff Gerac,&nbsp;Shanu Kothari,&nbsp;Dawn Blackhurst","doi":"10.1097/CCE.0000000000000941","DOIUrl":"https://doi.org/10.1097/CCE.0000000000000941","url":null,"abstract":"<p><p>Earlier treatment of sepsis leads to decreased mortality. Epic is an electronic medical record providing a predictive alert system for sepsis, the Epic Sepsis Model (ESM) Inpatient Predictive Analytic Tool. External validation of this system is lacking. This study aims to evaluate the ESM as a sepsis screening tool and determine whether an association exists between ESM alert system implementation and subsequent sepsis-related mortality.</p><p><strong>Design: </strong>Before-and-after study comparing baseline and intervention period.</p><p><strong>Setting: </strong>Urban 746-bed academic level 1 trauma center.</p><p><strong>Patients: </strong>Adult acute care inpatients discharged between January 12, 2018, and July 31, 2019.</p><p><strong>Interventions: </strong>During the before period, ESM was turned on in the background, but nurses and providers were not alerted of results. The system was then activated to alert providers of scores greater than or equal to 5, a set point determined using receiver operating characteristic curve analysis (area under the curve, 0.834; <i>p</i> < 0.001).</p><p><strong>Measurements and main results: </strong>Primary outcome was mortality during hospitalization; secondary outcomes were sepsis order set utilization, length of stay, and timing of administration of sepsis-appropriate antibiotics. Of the 11,512 inpatient encounters assessed by ESM, 10.2% (1,171) had sepsis based on diagnosis codes. As a screening test, the ESM had sensitivity, specificity, positive predictive value, and negative predictive value rates of 86.0%, 80.8%, 33.8%, and 98.11%, respectively. After ESM implementation, unadjusted mortality rates in patients with ESM score greater than or equal to 5 and who had not yet received sepsis-appropriate antibiotics declined from 24.3% to 15.9%; multivariable analysis yielded an odds ratio of sepsis-related mortality (95% CI) of 0.56 (0.39-0.80).</p><p><strong>Conclusions: </strong>In this single-center before-and-after study, utilization of the ESM score as a screening test was associated with a 44% reduction in the odds of sepsis-related mortality. Due to wide utilization of Epic, this is a potentially promising tool to improve sepsis mortality in the United States. This study is hypothesis generating, and further work with more rigorous study design is needed.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 7","pages":"e0941"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b7/7a/cc9-5-e0941.PMC10317482.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9799641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Causes of Death Among Medical ICU Patients With Pneumonia Due to COVID-19 in a Safety-Net Hospital. 某安全网医院重症监护病房新冠肺炎患者死亡原因分析
Pub Date : 2023-07-01 DOI: 10.1097/CCE.0000000000000947
Joseph P Cannizzo, Audrey L Chai, Christopher T Do, Melissa L Wilson, Janice M Liebler, Luis E Huerta

We sought to identify the primary causes of death of adult patients admitted to the medical ICU with symptomatic COVID-19 who ultimately suffered in-hospital mortality over the span of three major waves of COVID-19: Wild-type, alpha/epsilon, and delta.

Design: Retrospective single-center cohort study from March 2020 to December 2021.

Setting: One medical ICU in a 600-bed Tertiary Care Hospital in Los Angeles, CA.

Patients: Adult (n = 306) ICU patients admitted with symptomatic COVID-19 who suffered in-hospital mortality.

Interventions: None.

Main results: Of the 306 patients with COVID-19 who died in the hospital, 86.3% were Hispanic/Latino. The leading cause of death was respiratory failure, occurring in 57.8% of patients. There was no significant change in the rate of pulmonary deaths across the three waves of COVID-19 in our study period. The mean time from symptom onset to admission was 6.5 days, with an average hospital length of stay of 18 days. This did not differ between pulmonary and other causes of death. Sepsis was the second most common cause of death at 23.9% with a significant decrease from the wild-type wave to the delta wave. Among patients with sepsis as the cause of death, 22% (n = 16) were associated with fungemia. There was no significant association between steroid administration and cause of death. Lastly, the alpha/epsilon wave from December 2020 to May 2021 had the highest mortality rate when compared with wild-type or delta waves.

Conclusions: We found the primary cause of death in ICU patients with COVID-19 was acute respiratory failure, without significant changes over the span of three waves of COVID-19. This finding contrasts with reported causes of death for patients with non-COVID-19 acute respiratory distress syndrome, in which respiratory failure is an uncommon cause of death. In addition, we identified a subset of patients (5%) who died primarily due to fungemia, providing an area for further investigation.

我们试图确定有症状的COVID-19住院ICU的成年患者的主要死亡原因,这些患者最终在COVID-19的三次主要浪潮(野生型、alpha/epsilon和delta)中住院死亡。设计:2020年3月至2021年12月的回顾性单中心队列研究。环境:位于加利福尼亚州洛杉矶一家拥有600张床位的三级医院的一间重症监护室。患者:患有COVID-19症状并住院死亡的成人(n = 306)重症监护室患者。干预措施:没有。主要结果:在医院死亡的306例COVID-19患者中,86.3%为西班牙裔/拉丁裔。死亡的主要原因是呼吸衰竭,占57.8%。在我们的研究期间,三波COVID-19的肺部死亡率没有显著变化。从出现症状到入院的平均时间为6.5天,平均住院时间为18天。这在肺死亡和其他死因之间没有差异。脓毒症是第二大最常见的死亡原因,占23.9%,从野生型波到三角洲波显著下降。在以败血症为死亡原因的患者中,22% (n = 16)伴有真菌血症。类固醇的使用和死亡原因之间没有明显的联系。最后,与野生型或delta波相比,2020年12月至2021年5月的alpha/epsilon波的死亡率最高。结论:我们发现重症监护病房COVID-19患者的主要死亡原因是急性呼吸衰竭,在三波COVID-19期间无明显变化。这一发现与报告的非covid -19急性呼吸窘迫综合征患者死亡原因形成对比,在非covid -19急性呼吸窘迫综合征中,呼吸衰竭是一种罕见的死亡原因。此外,我们确定了一部分主要死于真菌血症的患者(5%),这为进一步研究提供了一个领域。
{"title":"Causes of Death Among Medical ICU Patients With Pneumonia Due to COVID-19 in a Safety-Net Hospital.","authors":"Joseph P Cannizzo,&nbsp;Audrey L Chai,&nbsp;Christopher T Do,&nbsp;Melissa L Wilson,&nbsp;Janice M Liebler,&nbsp;Luis E Huerta","doi":"10.1097/CCE.0000000000000947","DOIUrl":"https://doi.org/10.1097/CCE.0000000000000947","url":null,"abstract":"<p><p>We sought to identify the primary causes of death of adult patients admitted to the medical ICU with symptomatic COVID-19 who ultimately suffered in-hospital mortality over the span of three major waves of COVID-19: Wild-type, alpha/epsilon, and delta.</p><p><strong>Design: </strong>Retrospective single-center cohort study from March 2020 to December 2021.</p><p><strong>Setting: </strong>One medical ICU in a 600-bed Tertiary Care Hospital in Los Angeles, CA.</p><p><strong>Patients: </strong>Adult (<i>n</i> = 306) ICU patients admitted with symptomatic COVID-19 who suffered in-hospital mortality.</p><p><strong>Interventions: </strong>None.</p><p><strong>Main results: </strong>Of the 306 patients with COVID-19 who died in the hospital, 86.3% were Hispanic/Latino. The leading cause of death was respiratory failure, occurring in 57.8% of patients. There was no significant change in the rate of pulmonary deaths across the three waves of COVID-19 in our study period. The mean time from symptom onset to admission was 6.5 days, with an average hospital length of stay of 18 days. This did not differ between pulmonary and other causes of death. Sepsis was the second most common cause of death at 23.9% with a significant decrease from the wild-type wave to the delta wave. Among patients with sepsis as the cause of death, 22% (<i>n</i> = 16) were associated with fungemia. There was no significant association between steroid administration and cause of death. Lastly, the alpha/epsilon wave from December 2020 to May 2021 had the highest mortality rate when compared with wild-type or delta waves.</p><p><strong>Conclusions: </strong>We found the primary cause of death in ICU patients with COVID-19 was acute respiratory failure, without significant changes over the span of three waves of COVID-19. This finding contrasts with reported causes of death for patients with non-COVID-19 acute respiratory distress syndrome, in which respiratory failure is an uncommon cause of death. In addition, we identified a subset of patients (5%) who died primarily due to fungemia, providing an area for further investigation.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 7","pages":"e0947"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/04/cc9-5-e0947.PMC10351933.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10213612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Alternatives to Hydrocortisone for Hemodynamic Support in Septic Shock Management Due to Medication Shortage. 由于药物短缺,氢可的松在脓毒性休克治疗中的血流动力学支持的替代品。
Pub Date : 2023-07-01 DOI: 10.1097/CCE.0000000000000940
Mohammed Aldhaeefi, Abdulrahman Alshaya, Sanaa Belrhiti, Dhakrit Rungkitwattanakul

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection. Septic shock is when initial fluid resuscitation fails to increase the mean atrial pressure to greater than or equal to 65 mm Hg. The 2021 Surviving Sepsis Campaign guidelines recommend corticosteroids for vasopressor and fluid-refractory septic shock patients. Medication shortages can arise, and their etiologies include natural disasters, quality control issues, and manufacturing discontinuation. The U.S. Food and Drug Administration and the American Society of Health-System Pharmacists announced a shortage of IV hydrocortisone. Methylprednisolone and dexamethasone are considered therapeutic alternatives to hydrocortisone. This commentary aims to guide clinicians on the alternative to hydrocortisone among septic shock patients due to medication shortage.

败血症是一种危及生命的器官功能障碍,由宿主对感染的反应失调引起。脓毒性休克是指最初的液体复苏未能使平均心房压升高到大于或等于65 mm Hg。2021年存活脓毒症运动指南推荐对血管加压和液体难治性脓毒性休克患者使用皮质类固醇。可能出现药物短缺,其原因包括自然灾害、质量控制问题和生产中断。美国食品和药物管理局和美国卫生系统药剂师协会宣布静脉注射氢化可的松短缺。甲基强的松龙和地塞米松被认为是氢化可的松的治疗选择。这篇评论的目的是指导临床医生替代氢化可的松脓毒性休克患者由于药物短缺。
{"title":"Alternatives to Hydrocortisone for Hemodynamic Support in Septic Shock Management Due to Medication Shortage.","authors":"Mohammed Aldhaeefi,&nbsp;Abdulrahman Alshaya,&nbsp;Sanaa Belrhiti,&nbsp;Dhakrit Rungkitwattanakul","doi":"10.1097/CCE.0000000000000940","DOIUrl":"https://doi.org/10.1097/CCE.0000000000000940","url":null,"abstract":"<p><p>Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection. Septic shock is when initial fluid resuscitation fails to increase the mean atrial pressure to greater than or equal to 65 mm Hg. The 2021 Surviving Sepsis Campaign guidelines recommend corticosteroids for vasopressor and fluid-refractory septic shock patients. Medication shortages can arise, and their etiologies include natural disasters, quality control issues, and manufacturing discontinuation. The U.S. Food and Drug Administration and the American Society of Health-System Pharmacists announced a shortage of IV hydrocortisone. Methylprednisolone and dexamethasone are considered therapeutic alternatives to hydrocortisone. This commentary aims to guide clinicians on the alternative to hydrocortisone among septic shock patients due to medication shortage.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 7","pages":"e0940"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/4e/cc9-5-e0940.PMC10292733.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10103582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic Nonsteroidal Anti-Inflammatories for Analgesia in Postoperative Critical Care Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials. 用于术后重症监护患者镇痛的全身性非甾体抗炎药:随机对照试验的系统回顾和元分析》。
Pub Date : 2023-06-28 eCollection Date: 2023-07-01 DOI: 10.1097/CCE.0000000000000938
Chen Hsiang Ma, Kimberly B Tworek, Janice Y Kung, Sebastian Kilcommons, Kathleen Wheeler, Arabesque Parker, Janek Senaratne, Erika Macintyre, Wendy Sligl, Constantine J Karvellas, Fernando G Zampieri, Demetrios Jim Kutsogiannis, John Basmaji, Kimberley Lewis, Dipayan Chaudhuri, Sameer Sharif, Oleksa G Rewa, Bram Rochwerg, Sean M Bagshaw, Vincent I Lau

While opioids are part of usual care for analgesia in the ICU, there are concerns regarding excess use. This is a systematic review of nonsteroidal anti-inflammatory drugs (NSAIDs) use in postoperative critical care adult patients.

Data sources: We searched Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, trial registries, Google Scholar, and relevant systematic reviews through March 2023.

Study selection: Titles, abstracts, and full texts were reviewed independently and induplicate by two investigators to identify eligible studies. We included randomized control trials (RCTs) that compared NSAIDs alone or as an adjunct to opioids for systemic analgesia. The primary outcome was opioid utilization.

Data extraction: In duplicate, investigators independently extracted study characteristics, patient demographics, intervention details, and outcomes of interest using predefined abstraction forms. Statistical analyses were conducted using Review Manager software Version 5.4. (The Cochrane Collaboration, Copenhagen, Denmark).

Data synthesis: We included 15 RCTs (n = 1,621 patients) for admission to the ICU for postoperative management after elective procedures. Adjunctive NSAID therapy to opioids reduced 24-hour oral morphine equivalent consumption by 21.4 mg (95% CI, 11.8-31.0 mg reduction; high certainty) and probably reduced pain scores (measured by Visual Analog Scale) by 6.1 mm (95% CI, 12.2 decrease to 0.1 increase; moderate certainty). Adjunctive NSAID therapy probably had no impact on the duration of mechanical ventilation (1.6 hr reduction; 95% CI, 0.4 hr to 2.7 reduction; moderate certainty) and may have no impact on ICU length of stay (2.1 hr reduction; 95% CI, 6.1 hr reduction to 2.0 hr increase; low certainty). Variability in reporting adverse outcomes (e.g., gastrointestinal bleeding, acute kidney injury) precluded their meta-analysis.

Conclusions: In postoperative critical care adult patients, systemic NSAIDs reduced opioid use and probably reduced pain scores. However, the evidence is uncertain for the duration of mechanical ventilation or ICU length of stay. Further research is required to characterize the prevalence of NSAID-related adverse outcomes.

虽然阿片类药物是重症监护室常规镇痛护理的一部分,但过量使用也令人担忧。这是一篇关于非甾体抗炎药(NSAIDs)在术后重症监护成人患者中使用情况的系统性综述:我们搜索了医学文献分析与检索系统在线版、Excerpta Medica 数据库、护理与专职医疗文献累积索引、Cochrane 图书馆、试验登记处、谷歌学术以及截至 2023 年 3 月的相关系统性综述:标题、摘要和全文由两名研究人员独立重复审阅,以确定符合条件的研究。我们纳入的随机对照试验(RCT)比较了非甾体抗炎药单独或作为阿片类药物的辅助药物用于全身镇痛的情况。数据提取:一式两份,研究人员使用预定义的摘要表独立提取研究特征、患者人口统计学特征、干预细节和相关结果。使用Review Manager软件5.4版进行统计分析。(数据综合:我们纳入了 15 项 RCT(n = 1,621 名患者),这些研究针对择期手术后入住 ICU 进行术后管理。阿片类药物辅助非甾体抗炎药治疗可使24小时口服吗啡当量消耗量减少21.4毫克(95% CI,减少11.8-31.0毫克;高度确定性),并可能使疼痛评分(通过视觉模拟量表测量)减少6.1毫米(95% CI,减少12.2-增加0.1;中度确定性)。辅助非甾体抗炎药治疗可能不会影响机械通气的持续时间(减少 1.6 小时;95% CI,减少 0.4 小时至 2.7 小时;中等确定性),也可能不会影响重症监护室的住院时间(减少 2.1 小时;95% CI,减少 6.1 小时至增加 2.0 小时;低确定性)。不良结果(如消化道出血、急性肾损伤)报告的不一致性排除了他们的荟萃分析:结论:在术后重症监护成人患者中,全身性非甾体抗炎药可减少阿片类药物的使用,并可能降低疼痛评分。结论:在术后重症监护成人患者中,全身性非甾体抗炎药可减少阿片类药物的使用,并可能减少疼痛评分。需要进一步研究非甾体抗炎药相关不良后果的发生率。
{"title":"Systemic Nonsteroidal Anti-Inflammatories for Analgesia in Postoperative Critical Care Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials.","authors":"Chen Hsiang Ma, Kimberly B Tworek, Janice Y Kung, Sebastian Kilcommons, Kathleen Wheeler, Arabesque Parker, Janek Senaratne, Erika Macintyre, Wendy Sligl, Constantine J Karvellas, Fernando G Zampieri, Demetrios Jim Kutsogiannis, John Basmaji, Kimberley Lewis, Dipayan Chaudhuri, Sameer Sharif, Oleksa G Rewa, Bram Rochwerg, Sean M Bagshaw, Vincent I Lau","doi":"10.1097/CCE.0000000000000938","DOIUrl":"10.1097/CCE.0000000000000938","url":null,"abstract":"<p><p>While opioids are part of usual care for analgesia in the ICU, there are concerns regarding excess use. This is a systematic review of nonsteroidal anti-inflammatory drugs (NSAIDs) use in postoperative critical care adult patients.</p><p><strong>Data sources: </strong>We searched Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, trial registries, Google Scholar, and relevant systematic reviews through March 2023.</p><p><strong>Study selection: </strong>Titles, abstracts, and full texts were reviewed independently and induplicate by two investigators to identify eligible studies. We included randomized control trials (RCTs) that compared NSAIDs alone or as an adjunct to opioids for systemic analgesia. The primary outcome was opioid utilization.</p><p><strong>Data extraction: </strong>In duplicate, investigators independently extracted study characteristics, patient demographics, intervention details, and outcomes of interest using predefined abstraction forms. Statistical analyses were conducted using Review Manager software Version 5.4. (The Cochrane Collaboration, Copenhagen, Denmark).</p><p><strong>Data synthesis: </strong>We included 15 RCTs (<i>n</i> = 1,621 patients) for admission to the ICU for postoperative management after elective procedures. Adjunctive NSAID therapy to opioids reduced 24-hour oral morphine equivalent consumption by 21.4 mg (95% CI, 11.8-31.0 mg reduction; high certainty) and probably reduced pain scores (measured by Visual Analog Scale) by 6.1 mm (95% CI, 12.2 decrease to 0.1 increase; moderate certainty). Adjunctive NSAID therapy probably had no impact on the duration of mechanical ventilation (1.6 hr reduction; 95% CI, 0.4 hr to 2.7 reduction; moderate certainty) and may have no impact on ICU length of stay (2.1 hr reduction; 95% CI, 6.1 hr reduction to 2.0 hr increase; low certainty). Variability in reporting adverse outcomes (e.g., gastrointestinal bleeding, acute kidney injury) precluded their meta-analysis.</p><p><strong>Conclusions: </strong>In postoperative critical care adult patients, systemic NSAIDs reduced opioid use and probably reduced pain scores. However, the evidence is uncertain for the duration of mechanical ventilation or ICU length of stay. Further research is required to characterize the prevalence of NSAID-related adverse outcomes.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 7","pages":"e0938"},"PeriodicalIF":0.0,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/98/cc9-5-e0938.PMC10309528.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA Sequencing Analysis of CD4+ T Cells Exposed to Airway Fluid From Children With Pediatric Acute Respiratory Distress Syndrome. 暴露于儿童急性呼吸窘迫综合征患儿气道液中的CD4+ T细胞的RNA测序分析
Pub Date : 2023-06-23 eCollection Date: 2023-07-01 DOI: 10.1097/CCE.0000000000000935
Michael J Ripple, Min Huang, Susan T Stephenson, Ahmad F Mohammad, Mallory Tidwell, Anne M Fitzpatrick, Rishikesan Kamaleswaran, Jocelyn R Grunwell

CD4+ T cells contribute to lung inflammation in acute respiratory distress syndrome. The CD4+ T-cell response in pediatric acute respiratory distress syndrome (PARDS) is unknown.

Objectives: To identify differentially expressed genes and networks using a novel transcriptomic reporter assay with donor CD4+ T cells exposed to the airway fluid of intubated children with mild versus severe PARDS.

Design: In vitro pilot study.

Setting: Laboratory-based study using human airway fluid samples admitted to a 36-bed university-affiliated pediatric intensive care unit.

Patients/subjects: Seven children with severe PARDS, nine children with mild PARDS, and four intubated children without lung injury as controls.

Interventions: None.

Measurements and main results: We performed bulk RNA sequencing using a transcriptomic reporter assay of CD4+ T cells exposed to airway fluid from intubated children to discover gene networks differentiating severe from mild PARDS. We found that innate immunity pathways, type I (α and β), and type II (γ) interferon response and cytokine/chemokine signaling are downregulated in CD4+ T cells exposed to airway fluid from intubated children with severe PARDS compared with those with mild PARDS.

Conclusions: We identified gene networks important to the PARDS airway immune response using bulk RNA sequencing from a novel CD4+ T-cell reporter assay that exposed CD4+ T cells to airway fluid from intubated children with severe and mild PARDS. These pathways will help drive mechanistic investigations into PARDS. Validation of our findings using this transcriptomic reporter assay strategy is needed.

CD4+ T细胞参与急性呼吸窘迫综合征的肺部炎症。儿童急性呼吸窘迫综合征(PARDS)的CD4+ t细胞反应尚不清楚。目的:利用一种新的转录组学报告测定方法,鉴定轻度和重度PARDS患儿插管后气道液中供体CD4+ T细胞的差异表达基因和网络。设计:体外试验。环境:基于实验室的研究,使用36张床位的大学附属儿科重症监护室收治的人类气道液体样本。患者/受试者:重度PARDS患儿7例,轻度PARDS患儿9例,气管插管无肺损伤患儿4例作为对照。干预措施:没有。测量结果和主要结果:我们对暴露于插管儿童气道液中的CD4+ T细胞进行了大量RNA测序,使用转录组报告分析来发现区分重度和轻度PARDS的基因网络。我们发现,与轻度PARDS患者相比,暴露于气管插管严重PARDS患儿气道液中的CD4+ T细胞的先天免疫途径、I型(α和β)和II型(γ)干扰素反应和细胞因子/趋化因子信号传导下调。结论:我们通过一项新的CD4+ T细胞报告试验的大量RNA测序,确定了对PARDS气道免疫反应重要的基因网络,该试验将CD4+ T细胞暴露于重症和轻度PARDS插管儿童的气道液中。这些途径将有助于推动对PARDS的机制研究。需要使用这种转录组报告分析策略验证我们的发现。
{"title":"RNA Sequencing Analysis of CD4<sup>+</sup> T Cells Exposed to Airway Fluid From Children With Pediatric Acute Respiratory Distress Syndrome.","authors":"Michael J Ripple, Min Huang, Susan T Stephenson, Ahmad F Mohammad, Mallory Tidwell, Anne M Fitzpatrick, Rishikesan Kamaleswaran, Jocelyn R Grunwell","doi":"10.1097/CCE.0000000000000935","DOIUrl":"10.1097/CCE.0000000000000935","url":null,"abstract":"<p><p>CD4<sup>+</sup> T cells contribute to lung inflammation in acute respiratory distress syndrome. The CD4<sup>+</sup> T-cell response in pediatric acute respiratory distress syndrome (PARDS) is unknown.</p><p><strong>Objectives: </strong>To identify differentially expressed genes and networks using a novel transcriptomic reporter assay with donor CD4<sup>+</sup> T cells exposed to the airway fluid of intubated children with mild versus severe PARDS.</p><p><strong>Design: </strong>In vitro pilot study.</p><p><strong>Setting: </strong>Laboratory-based study using human airway fluid samples admitted to a 36-bed university-affiliated pediatric intensive care unit.</p><p><strong>Patients/subjects: </strong>Seven children with severe PARDS, nine children with mild PARDS, and four intubated children without lung injury as controls.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>We performed bulk RNA sequencing using a transcriptomic reporter assay of CD4<sup>+</sup> T cells exposed to airway fluid from intubated children to discover gene networks differentiating severe from mild PARDS. We found that innate immunity pathways, type I (α and β), and type II (γ) interferon response and cytokine/chemokine signaling are downregulated in CD4<sup>+</sup> T cells exposed to airway fluid from intubated children with severe PARDS compared with those with mild PARDS.</p><p><strong>Conclusions: </strong>We identified gene networks important to the PARDS airway immune response using bulk RNA sequencing from a novel CD4<sup>+</sup> T-cell reporter assay that exposed CD4<sup>+</sup> T cells to airway fluid from intubated children with severe and mild PARDS. These pathways will help drive mechanistic investigations into PARDS. Validation of our findings using this transcriptomic reporter assay strategy is needed.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 7","pages":"e0935"},"PeriodicalIF":0.0,"publicationDate":"2023-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/3d/cc9-5-e0935.PMC10292738.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10103594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors and Temporal Trends of Withdrawal of Life-Sustaining Therapy After Acute Stroke in the Florida Stroke Registry. 佛罗里达州中风登记处急性中风后撤除维持生命疗法的预测因素和时间趋势。
Pub Date : 2023-06-23 eCollection Date: 2023-07-01 DOI: 10.1097/CCE.0000000000000934
Ayham Alkhachroum, Lili Zhou, Negar Asdaghi, Hannah Gardener, Hao Ying, Carolina M Gutierrez, Brian M Manolovitz, Daniel Samano, Danielle Bass, Dianne Foster, Nicole B Sur, David Z Rose, Angus Jameson, Nina Massad, Mohan Kottapally, Amedeo Merenda, Robert M Starke, Kristine O'Phelan, Jose G Romano, Jan Claassen, Ralph L Sacco, Tatjana Rundek

Temporal trends and factors associated with the withdrawal of life-sustaining therapy (WLST) after acute stroke are not well determined.

Design: Observational study (2008-2021).

Setting: Florida Stroke Registry (152 hospitals).

Patients: Acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH) patients.

Interventions: None.

Measurements and main results: Importance plots were performed to generate the most predictive factors of WLST. Area under the curve (AUC) for the receiver operating curve were generated for the performance of logistic regression (LR) and random forest (RF) models. Regression analysis was applied to evaluate temporal trends. Among 309,393 AIS patients, 47,485 ICH patients, and 16,694 SAH patients; 9%, 28%, and 19% subsequently had WLST. Patients who had WLST were older (77 vs 70 yr), more women (57% vs 49%), White (76% vs 67%), with greater stroke severity on the National Institutes of Health Stroke Scale greater than or equal to 5 (29% vs 19%), more likely hospitalized in comprehensive stroke centers (52% vs 44%), had Medicare insurance (53% vs 44%), and more likely to have impaired level of consciousness (38% vs 12%). Most predictors associated with the decision to WLST in AIS were age, stroke severity, region, insurance status, center type, race, and level of consciousness (RF AUC of 0.93 and LR AUC of 0.85). Predictors in ICH included age, impaired level of consciousness, region, race, insurance status, center type, and prestroke ambulation status (RF AUC of 0.76 and LR AUC of 0.71). Factors in SAH included age, impaired level of consciousness, region, insurance status, race, and stroke center type (RF AUC of 0.82 and LR AUC of 0.72). Despite a decrease in the rates of early WLST (< 2 d) and mortality, the overall rates of WLST remained stable.

Conclusions: In acute hospitalized stroke patients in Florida, factors other than brain injury alone contribute to the decision to WLST. Potential predictors not measured in this study include education, culture, faith and beliefs, and patient/family and physician preferences. The overall rates of WLST have not changed in the last 2 decades.

急性中风后撤消维持生命疗法(WLST)的时间趋势和相关因素尚未明确:观察性研究(2008-2021 年):佛罗里达州卒中登记处(152 家医院):急性缺血性卒中(AIS)、脑出血(ICH)和蛛网膜下腔出血(SAH)患者:测量和主要结果测量和主要结果:绘制了重要性图,以得出最能预测 WLST 的因素。为逻辑回归(LR)和随机森林(RF)模型的性能生成了接收者操作曲线下面积(AUC)。回归分析用于评估时间趋势。在 309,393 例 AIS 患者、47,485 例 ICH 患者和 16,694 例 SAH 患者中,分别有 9%、28% 和 19% 随后出现了 WLST。接受 WLST 的患者年龄更大(77 岁 vs 70 岁)、女性更多(57% vs 49%)、白人更多(76% vs 67%)、根据美国国立卫生研究院卒中量表大于或等于 5 级的卒中严重程度更高(29% vs 19%)、更有可能在综合卒中中心住院(52% vs 44%)、有医疗保险(53% vs 44%)、更有可能意识受损(38% vs 12%)。在 AIS 中,与决定 WLST 最相关的预测因素是年龄、卒中严重程度、地区、保险状况、中心类型、种族和意识水平(RF AUC 为 0.93,LR AUC 为 0.85)。ICH 的预测因素包括年龄、意识受损程度、地区、种族、保险状况、中心类型和卒中前行走状况(RF AUC 为 0.76,LR AUC 为 0.71)。导致 SAH 的因素包括年龄、意识受损程度、地区、保险状况、种族和卒中中心类型(RF AUC 为 0.82,LR AUC 为 0.72)。尽管早期 WLST(< 2 d)率和死亡率有所下降,但总体 WLST 率保持稳定:结论:在佛罗里达州的急性住院脑卒中患者中,除脑损伤外,其他因素也是决定是否进行 WLST 的因素。本研究未测量的潜在预测因素包括教育、文化、信仰和信念以及患者/家属和医生的偏好。在过去 20 年中,WLST 的总体使用率没有变化。
{"title":"Predictors and Temporal Trends of Withdrawal of Life-Sustaining Therapy After Acute Stroke in the Florida Stroke Registry.","authors":"Ayham Alkhachroum, Lili Zhou, Negar Asdaghi, Hannah Gardener, Hao Ying, Carolina M Gutierrez, Brian M Manolovitz, Daniel Samano, Danielle Bass, Dianne Foster, Nicole B Sur, David Z Rose, Angus Jameson, Nina Massad, Mohan Kottapally, Amedeo Merenda, Robert M Starke, Kristine O'Phelan, Jose G Romano, Jan Claassen, Ralph L Sacco, Tatjana Rundek","doi":"10.1097/CCE.0000000000000934","DOIUrl":"10.1097/CCE.0000000000000934","url":null,"abstract":"<p><p>Temporal trends and factors associated with the withdrawal of life-sustaining therapy (WLST) after acute stroke are not well determined.</p><p><strong>Design: </strong>Observational study (2008-2021).</p><p><strong>Setting: </strong>Florida Stroke Registry (152 hospitals).</p><p><strong>Patients: </strong>Acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH) patients.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>Importance plots were performed to generate the most predictive factors of WLST. Area under the curve (AUC) for the receiver operating curve were generated for the performance of logistic regression (LR) and random forest (RF) models. Regression analysis was applied to evaluate temporal trends. Among 309,393 AIS patients, 47,485 ICH patients, and 16,694 SAH patients; 9%, 28%, and 19% subsequently had WLST. Patients who had WLST were older (77 vs 70 yr), more women (57% vs 49%), White (76% vs 67%), with greater stroke severity on the National Institutes of Health Stroke Scale greater than or equal to 5 (29% vs 19%), more likely hospitalized in comprehensive stroke centers (52% vs 44%), had Medicare insurance (53% vs 44%), and more likely to have impaired level of consciousness (38% vs 12%). Most predictors associated with the decision to WLST in AIS were age, stroke severity, region, insurance status, center type, race, and level of consciousness (RF AUC of 0.93 and LR AUC of 0.85). Predictors in ICH included age, impaired level of consciousness, region, race, insurance status, center type, and prestroke ambulation status (RF AUC of 0.76 and LR AUC of 0.71). Factors in SAH included age, impaired level of consciousness, region, insurance status, race, and stroke center type (RF AUC of 0.82 and LR AUC of 0.72). Despite a decrease in the rates of early WLST (< 2 d) and mortality, the overall rates of WLST remained stable.</p><p><strong>Conclusions: </strong>In acute hospitalized stroke patients in Florida, factors other than brain injury alone contribute to the decision to WLST. Potential predictors not measured in this study include education, culture, faith and beliefs, and patient/family and physician preferences. The overall rates of WLST have not changed in the last 2 decades.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 7","pages":"e0934"},"PeriodicalIF":0.0,"publicationDate":"2023-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/ea/cc9-5-e0934.PMC10292735.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10103585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trend in Clinical Trial Participation During COVID-19: A Secondary Analysis of the I-SPY COVID Clinical Trial. COVID-19 期间临床试验参与趋势:对 I-SPY COVID 临床试验的二次分析。
Pub Date : 2023-06-19 eCollection Date: 2023-06-01 DOI: 10.1097/CCE.0000000000000930
Philip Yang, Neal W Dickert, Angela Haczku, Christine Spainhour, Sara C Auld

To analyze the temporal trend in enrollment rates in a COVID-19 platform trial during the first three waves of the pandemic in the United States.

Design: Secondary analysis of data from the I-SPY COVID randomized controlled trial (RCT).

Setting: Thirty-one hospitals throughout the United States.

Patients: Patients who were approached, either directly or via a legally authorized representative, for consent and enrollment into the I-SPY COVID RCT.

Interventions: None.

Measurements and main results: Among 1,338 patients approached for the I-SPY COVID trial from July 30, 2020, to February 17, 2022, the number of patients who enrolled (n = 1,063) versus declined participation (n = 275) was used to calculate monthly enrollment rates. Overall, demographic and baseline clinical characteristics were similar between those who enrolled versus declined. Enrollment rates fluctuated over the course of the COVID-19 pandemic, but there were no significant trends over time (Mann-Kendall test, p = 0.21). Enrollment rates were also comparable between vaccinated and unvaccinated patients. In multivariable logistic regression analysis, age, sex, region of residence, COVID-19 severity of illness, and vaccination status were not significantly associated with the decision to decline consent.

Conclusions: In this secondary analysis of the I-SPY COVID clinical trial, there was no significant association between the enrollment rate and time period or vaccination status among all eligible patients approached for clinical trial participation. Additional studies are needed to better understand whether the COVID-19 pandemic has altered clinical trial participation and to develop strategies for encouraging participation in future COVID-19 and critical care clinical trials.

分析美国大流行前三波期间COVID-19平台试验注册率的时间趋势:对I-SPY COVID随机对照试验(RCT)数据进行二次分析:环境:全美 31 家医院:患者:直接或通过合法授权代表征得同意并加入 I-SPY COVID RCT 的患者:测量和主要结果在 2020 年 7 月 30 日至 2022 年 2 月 17 日期间接触的 1,338 名 I-SPY COVID 试验患者中,使用注册患者人数(n = 1,063 人)与拒绝参与患者人数(n = 275 人)计算每月注册率。总体而言,加入与拒绝加入的患者的人口统计学特征和基线临床特征相似。注册率在 COVID-19 大流行期间有所波动,但没有明显的变化趋势(Mann-Kendall 检验,p = 0.21)。已接种疫苗和未接种疫苗的患者的登记率也相当。在多变量逻辑回归分析中,年龄、性别、居住地区、COVID-19 疾病严重程度和疫苗接种情况与拒绝同意的决定无明显关联:在对 I-SPY COVID 临床试验的二次分析中,所有符合临床试验条件的患者的入组率与时间段或疫苗接种情况之间没有明显关联。为了更好地了解 COVID-19 大流行是否改变了临床试验的参与情况,并制定鼓励参与未来 COVID-19 和重症监护临床试验的策略,还需要进行更多的研究。
{"title":"Trend in Clinical Trial Participation During COVID-19: A Secondary Analysis of the I-SPY COVID Clinical Trial.","authors":"Philip Yang, Neal W Dickert, Angela Haczku, Christine Spainhour, Sara C Auld","doi":"10.1097/CCE.0000000000000930","DOIUrl":"10.1097/CCE.0000000000000930","url":null,"abstract":"<p><p>To analyze the temporal trend in enrollment rates in a COVID-19 platform trial during the first three waves of the pandemic in the United States.</p><p><strong>Design: </strong>Secondary analysis of data from the I-SPY COVID randomized controlled trial (RCT).</p><p><strong>Setting: </strong>Thirty-one hospitals throughout the United States.</p><p><strong>Patients: </strong>Patients who were approached, either directly or via a legally authorized representative, for consent and enrollment into the I-SPY COVID RCT.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>Among 1,338 patients approached for the I-SPY COVID trial from July 30, 2020, to February 17, 2022, the number of patients who enrolled (<i>n</i> = 1,063) versus declined participation (<i>n</i> = 275) was used to calculate monthly enrollment rates. Overall, demographic and baseline clinical characteristics were similar between those who enrolled versus declined. Enrollment rates fluctuated over the course of the COVID-19 pandemic, but there were no significant trends over time (Mann-Kendall test, <i>p</i> = 0.21). Enrollment rates were also comparable between vaccinated and unvaccinated patients. In multivariable logistic regression analysis, age, sex, region of residence, COVID-19 severity of illness, and vaccination status were not significantly associated with the decision to decline consent.</p><p><strong>Conclusions: </strong>In this secondary analysis of the I-SPY COVID clinical trial, there was no significant association between the enrollment rate and time period or vaccination status among all eligible patients approached for clinical trial participation. Additional studies are needed to better understand whether the COVID-19 pandemic has altered clinical trial participation and to develop strategies for encouraging participation in future COVID-19 and critical care clinical trials.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 6","pages":"e0930"},"PeriodicalIF":0.0,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b3/30/cc9-5-e0930.PMC10281328.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9708813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DHCR7 Expression Predicts Poor Outcomes and Mortality From Sepsis. DHCR7表达预测败血症的不良预后和死亡率
Pub Date : 2023-06-14 eCollection Date: 2023-06-01 DOI: 10.1097/CCE.0000000000000929
Faheem W Guirgis, Vinitha Jacob, Dongyuan Wu, Morgan Henson, Kimberly Daly-Crews, Charlotte Hopson, Lauren Page Black, Elizabeth L DeVos, Dawoud Sulaiman, Guillaume Labilloy, Todd M Brusko, Jordan A Shavit, Andrew Bertrand, Matthew Feldhammer, Brett Baskovich, Kiley Graim, Susmita Datta, Srinivasa T Reddy

This is a study of lipid metabolic gene expression patterns to discover precision medicine for sepsis.

Objectives: Sepsis patients experience poor outcomes including chronic critical illness (CCI) or early death (within 14 d). We investigated lipid metabolic gene expression differences by outcome to discover therapeutic targets.

Design setting and particitpants: Secondary analysis of samples from prospectively enrolled sepsis patients (first 24 hr) and a zebrafish endotoxemia model for drug discovery. Patients were enrolled from the emergency department or ICU at an urban teaching hospital. Enrollment samples from sepsis patients were analyzed. Clinical data and cholesterol levels were recorded. Leukocytes were processed for RNA sequencing and reverse transcriptase polymerase chain reaction. A lipopolysaccharide zebrafish endotoxemia model was used for confirmation of human transcriptomic findings and drug discovery.

Main outcomes and measures: The derivation cohort included 96 patients and controls (12 early death, 13 CCI, 51 rapid recovery, and 20 controls) and the validation cohort had 52 patients (6 early death, 8 CCI, and 38 rapid recovery).

Results: The cholesterol metabolism gene 7-dehydrocholesterol reductase (DHCR7) was significantly up-regulated in both derivation and validation cohorts in poor outcome sepsis compared with rapid recovery patients and in 90-day nonsurvivors (validation only) and validated using RT-qPCR analysis. Our zebrafish sepsis model showed up-regulation of dhcr7 and several of the same lipid genes up-regulated in poor outcome human sepsis (dhcr24, sqlea, cyp51, msmo1, and ldlra) compared with controls. We then tested six lipid-based drugs in the zebrafish endotoxemia model. Of these, only the Dhcr7 inhibitor AY9944 completely rescued zebrafish from lipopolysaccharide death in a model with 100% lethality.

Conclusions: DHCR7, an important cholesterol metabolism gene, was up-regulated in poor outcome sepsis patients warranting external validation. This pathway may serve as a potential therapeutic target to improve sepsis outcomes.

这是一项研究脂质代谢基因表达模式,以发现败血症的精准药物。目的:脓毒症患者预后不佳,包括慢性危重症(CCI)或早逝(14天内)。我们研究了不同结果的脂质代谢基因表达差异,以发现治疗靶点。设计背景和参与者:前瞻性入选败血症患者样本的二次分析(前24例) hr)和用于药物发现的斑马鱼内毒素血症模型。患者来自城市教学医院的急诊科或重症监护室。对败血症患者的入组样本进行分析。记录临床数据和胆固醇水平。对白细胞进行RNA测序和逆转录聚合酶链式反应。脂多糖-斑马鱼内毒素血症模型用于证实人类转录组学发现和药物发现。主要结果和指标:推导队列包括96名患者和对照组(12名早逝,13名CCI,51名快速康复,20名对照组),验证队列有52名患者(6名早逝、8名CCI和38名快速康复)结果败血症与快速康复患者和90天非幸存者的比较(仅验证),并使用RT-qPCR分析进行验证。与对照组相比,我们的斑马鱼败血症模型显示,在预后不佳的人类败血症中,dhcr7和几个相同的脂质基因(dhcr24、sqlea、cyp51、msmo1和ldlra)上调。然后,我们在斑马鱼内毒素血症模型中测试了六种基于脂质的药物。其中,只有Dhcr7抑制剂AY9944在具有100%致死性的模型中完全将斑马鱼从脂多糖死亡中拯救出来。结论:DHCR7是一种重要的胆固醇代谢基因,在预后不佳的败血症患者中上调,值得外部验证。该途径可能成为改善败血症预后的潜在治疗靶点。
{"title":"<i>DHCR7</i> Expression Predicts Poor Outcomes and Mortality From Sepsis.","authors":"Faheem W Guirgis, Vinitha Jacob, Dongyuan Wu, Morgan Henson, Kimberly Daly-Crews, Charlotte Hopson, Lauren Page Black, Elizabeth L DeVos, Dawoud Sulaiman, Guillaume Labilloy, Todd M Brusko, Jordan A Shavit, Andrew Bertrand, Matthew Feldhammer, Brett Baskovich, Kiley Graim, Susmita Datta, Srinivasa T Reddy","doi":"10.1097/CCE.0000000000000929","DOIUrl":"10.1097/CCE.0000000000000929","url":null,"abstract":"<p><p>This is a study of lipid metabolic gene expression patterns to discover precision medicine for sepsis.</p><p><strong>Objectives: </strong>Sepsis patients experience poor outcomes including chronic critical illness (CCI) or early death (within 14 d). We investigated lipid metabolic gene expression differences by outcome to discover therapeutic targets.</p><p><strong>Design setting and particitpants: </strong>Secondary analysis of samples from prospectively enrolled sepsis patients (first 24 hr) and a zebrafish endotoxemia model for drug discovery. Patients were enrolled from the emergency department or ICU at an urban teaching hospital. Enrollment samples from sepsis patients were analyzed. Clinical data and cholesterol levels were recorded. Leukocytes were processed for RNA sequencing and reverse transcriptase polymerase chain reaction. A lipopolysaccharide zebrafish endotoxemia model was used for confirmation of human transcriptomic findings and drug discovery.</p><p><strong>Main outcomes and measures: </strong>The derivation cohort included 96 patients and controls (12 early death, 13 CCI, 51 rapid recovery, and 20 controls) and the validation cohort had 52 patients (6 early death, 8 CCI, and 38 rapid recovery).</p><p><strong>Results: </strong>The cholesterol metabolism gene <i>7-dehydrocholesterol reductase (DHCR7</i>) was significantly up-regulated in both derivation and validation cohorts in poor outcome sepsis compared with rapid recovery patients and in 90-day nonsurvivors (validation only) and validated using RT-qPCR analysis. Our zebrafish sepsis model showed up-regulation of <i>dhcr7</i> and several of the same lipid genes up-regulated in poor outcome human sepsis (<i>dhcr24</i>, <i>sqlea, cyp51, msmo1</i>, and <i>ldlra</i>) compared with controls. We then tested six lipid-based drugs in the zebrafish endotoxemia model. Of these, only the <i>Dhcr7</i> inhibitor AY9944 completely rescued zebrafish from lipopolysaccharide death in a model with 100% lethality.</p><p><strong>Conclusions: </strong><i>DHCR7</i>, an important cholesterol metabolism gene, was up-regulated in poor outcome sepsis patients warranting external validation. This pathway may serve as a potential therapeutic target to improve sepsis outcomes.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 6","pages":"e0929"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/7e/cc9-5-e0929.PMC10270496.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9832101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Clinical Score for Quantifying Edema in Mechanically Ventilated Children With Congenital Heart Disease in Intensive Care. 用于量化重症监护中机械通气先天性心脏病患儿水肿的临床评分。
Pub Date : 2023-06-05 eCollection Date: 2023-06-01 DOI: 10.1097/CCE.0000000000000924
Ben Gelbart, Sudeep Kumar Kapalavai, Vanessa Marchesini, Jeffrey Presneill, Andrea Veysey, Alyssa Serratore, Jessica Appleyard, Rinaldo Bellomo, Warwick Butt, Trevor Duke

Standardized clinical measurements of edema do not exist.

Objectives: To describe a 19-point clinical edema score (CES), investigate its interobserver agreement, and compare changes between such CES and body weight.

Design setting and participants: Prospective observational study in a tertiary PICU of mechanically ventilated children with congenital heart disease.

Main outcomes and measures: Differences in the median CES between observer groups.

Results: We studied 61 children, with a median age of 8.0 days (interquartile range, 1.0-14.0 d). A total of 539 CES were performed by three observer groups (medical 1 [reference], medical 2, and bedside nurse) at 0, 24, and 48 hours from enrollment. Overall, there was close agreement between observer groups in mean, median, and upper quartile of CES scores, with least agreement observed in the lower quartile of scores. Across all quartiles of CES, after adjusting for baseline weight, cardiac surgical risk, duration of cardiopulmonary bypass, or peritoneal dialysis during the study, observer groups returned similar mean scores (medical 2: 25th centile +0.1 [95% CI, -0.2 to 0.5], median +0.6 [95% CI, -0.4 to 1.5], 75th centile +0.1 [95% CI, -1.1 to 1.4] and nurse: 25th centile +0.5 [95% CI, 0.0-0.9], median +0.7 [95% CI, 0.0-1.5], 75th centile -0.2 [95% CI, -1.3 to 1.0]) Within a multivariable mixed-effects linear regression model, including adjustment for baseline CES, each 1 point increase in CES was associated with a 12.1 grams (95% CI, 3.2-21 grams) increase in body weight.

Conclusions and relevance: In mechanically ventilated children with congenital heart disease, three groups of observers tended to agree when assessing overall edema using an ordinal clinical score assessed in six body regions, with agreement least at low edema scores. An increase in CES was associated with an increase in body weight, suggesting some validity for quantifying edema. Further exploration of the CES as a rapid clinical tool is indicated.

目前还没有标准化的临床水肿测量方法:描述19点临床水肿评分(CES),研究其观察者间的一致性,并比较CES与体重之间的变化:主要结果和测量指标:主要结果和测量指标:观察组之间 CES 中位数的差异:我们对61名儿童进行了研究,他们的中位年龄为8.0天(四分位间范围为1.0-14.0天)。三个观察组(医护 1 [参考]、医护 2 和床旁护士)在入院后 0、24 和 48 小时内共进行了 539 次 CES。总体而言,各观察组之间在 CES 评分的平均值、中位数和上四分位数上的一致性非常接近,而在下四分位数上的一致性最低。在对基线体重、心脏手术风险、心肺旁路持续时间或研究期间腹膜透析进行调整后,CES 的所有四分位数中,观察者组的平均得分相似(医护 2:第 25 百分位数 +0.1 [95% CI, -0.2 to 0.5],中位数 +0.6 [95% CI, -0.4 to 1.5],第 75 百分位数 +0.1 [95% CI, -1.1 to 1.4];护士:第 25 百分位数 +0.1 [95% CI, -0.2 to 0.5],中位数 +0.6 [95% CI, -0.4 to 1.5]。在多变量混合效应线性回归模型中,包括对基线 CES 的调整,CES 每增加 1 个点,体重就会增加 12.1 克(95% CI,3.2-21 克):在患有先天性心脏病的机械通气患儿中,三组观察者在使用对身体六个区域进行评估的序数临床评分来评估总体水肿时往往意见一致,在低水肿评分时意见最不一致。CES的增加与体重的增加有关,这表明量化水肿具有一定的有效性。将 CES 作为一种快速临床工具进行进一步探索是有必要的。
{"title":"A Clinical Score for Quantifying Edema in Mechanically Ventilated Children With Congenital Heart Disease in Intensive Care.","authors":"Ben Gelbart, Sudeep Kumar Kapalavai, Vanessa Marchesini, Jeffrey Presneill, Andrea Veysey, Alyssa Serratore, Jessica Appleyard, Rinaldo Bellomo, Warwick Butt, Trevor Duke","doi":"10.1097/CCE.0000000000000924","DOIUrl":"10.1097/CCE.0000000000000924","url":null,"abstract":"<p><p>Standardized clinical measurements of edema do not exist.</p><p><strong>Objectives: </strong>To describe a 19-point clinical edema score (CES), investigate its interobserver agreement, and compare changes between such CES and body weight.</p><p><strong>Design setting and participants: </strong>Prospective observational study in a tertiary PICU of mechanically ventilated children with congenital heart disease.</p><p><strong>Main outcomes and measures: </strong>Differences in the median CES between observer groups.</p><p><strong>Results: </strong>We studied 61 children, with a median age of 8.0 days (interquartile range, 1.0-14.0 d). A total of 539 CES were performed by three observer groups (medical 1 [reference], medical 2, and bedside nurse) at 0, 24, and 48 hours from enrollment. Overall, there was close agreement between observer groups in mean, median, and upper quartile of CES scores, with least agreement observed in the lower quartile of scores. Across all quartiles of CES, after adjusting for baseline weight, cardiac surgical risk, duration of cardiopulmonary bypass, or peritoneal dialysis during the study, observer groups returned similar mean scores (medical 2: 25th centile +0.1 [95% CI, -0.2 to 0.5], median +0.6 [95% CI, -0.4 to 1.5], 75th centile +0.1 [95% CI, -1.1 to 1.4] and nurse: 25th centile +0.5 [95% CI, 0.0-0.9], median +0.7 [95% CI, 0.0-1.5], 75th centile -0.2 [95% CI, -1.3 to 1.0]) Within a multivariable mixed-effects linear regression model, including adjustment for baseline CES, each 1 point increase in CES was associated with a 12.1 grams (95% CI, 3.2-21 grams) increase in body weight.</p><p><strong>Conclusions and relevance: </strong>In mechanically ventilated children with congenital heart disease, three groups of observers tended to agree when assessing overall edema using an ordinal clinical score assessed in six body regions, with agreement least at low edema scores. An increase in CES was associated with an increase in body weight, suggesting some validity for quantifying edema. Further exploration of the CES as a rapid clinical tool is indicated.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 6","pages":"e0924"},"PeriodicalIF":0.0,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/da/cc9-5-e0924.PMC10456982.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10110079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Multi-Hospital Survey of Current Practices for Supporting Recovery From Sepsis. 多家医院支持脓毒症康复的现状调查。
Pub Date : 2023-06-05 eCollection Date: 2023-06-01 DOI: 10.1097/CCE.0000000000000926
Rachel K Hechtman, Jennifer Cano, Taylor Whittington, Cainnear K Hogan, Sarah M Seelye, Jeremy B Sussman, Hallie C Prescott

Sepsis survivors are at increased risk for morbidity and functional impairment. There are recommended practices to support recovery after sepsis, but it is unclear how often they are implemented. We sought to assess the current use of recovery-based practices across hospitals.

Design: Electronic survey assessing the use of best practices for recovery from COVID-related and non-COVID-related sepsis. Questions included four-point Likert responses of "never" to "always/nearly always."

Setting: Twenty-six veterans affairs hospitals with the highest (n = 13) and lowest (n = 13) risk-adjusted 90-day sepsis survival.

Subjects: Inpatient and outpatient clinician leaders.

Interventions: None.

Measurements and main results: For each domain, we calculated the proportion of "always/nearly always" responses and mean Likert scores. We assessed for differences by hospital survival, COVID versus non-COVID sepsis, and sepsis case volume. Across eight domains of care, the proportion "always/nearly always" responses ranged from: 80.7% (social support) and 69.8% (medication management) to 22.5% (physical recovery and adaptation) and 0.0% (emotional support). Higher-survival hospitals more often performed screening for new symptoms/limitations (49.2% vs 35.1% "always/nearly always," p = 0.02) compared with lower-survival hospitals. There was no difference in "always/nearly always" responses for COVID-related versus non-COVID-related sepsis, but small differences in mean Likert score in four domains: care coordination (3.34 vs 3.48, p = 0.01), medication management (3.59 vs 3.65, p = 0.04), screening for new symptoms/limitations (3.13 vs 3.20, p = 0.02), and anticipatory guidance and education (2.97 vs 2.84, p < 0.001). Lower case volume hospitals more often performed care coordination (72.7% vs 43.8% "always/nearly always," p = 0.02), screening for new symptoms/limitations (60.6% vs 35.8%, p < 0.001), and social support (100% vs 74.2%, p = 0.01).

Conclusions: Our findings show variable adoption of practices for sepsis recovery. Future work is needed to understand why some practice domains are employed more frequently than others, and how to facilitate practice implementation, particularly within rarely adopted domains such as emotional support.

脓毒症幸存者的发病率和功能损害风险增加。有一些建议的做法可以支持败血症后的康复,但尚不清楚它们的实施频率。我们试图评估目前各医院使用基于康复的做法的情况。设计:电子调查,评估新冠肺炎相关和非新冠肺炎相关性败血症康复最佳实践的使用情况。问题包括Likert对“从不”到“总是/几乎总是”的四点回答。设置:26家退伍军人事务医院的败血症90天生存率最高(n=13)和最低(n=13。受试者:住院和门诊临床医生领导。干预措施:无。测量和主要结果:对于每个领域,我们计算了“总是/几乎总是”回答的比例和平均Likert分数。我们通过医院生存率、新冠肺炎与非新冠肺炎败血症以及败血症病例数来评估差异。在八个护理领域中,“总是/几乎总是”的反应比例从80.7%(社会支持)和69.8%(药物管理)到22.5%(身体恢复和适应)和0.0%(情感支持)不等。与生存率较低的医院相比,生存率较高的医院更经常进行新症状/局限性筛查(49.2%对35.1%“总是/几乎总是”,p=0.02)。与非新冠肺炎相关的败血症相比,“总是/几乎总是”的反应没有差异,但在四个领域的平均Likert评分略有差异:护理协调(3.34 vs 3.48,p=0.01)、药物管理(3.59 vs 3.65,p=0.04)、新症状/限制筛查(3.13 vs 3.20,p=0.02),以及预期指导和教育(2.97 vs 2.84,p<0.001)。病例量较低的医院更经常进行护理协调(72.7%vs 43.8%“总是/几乎总是”,p=0.02)、新症状/局限性筛查(60.6%vs 35.8%,p<001)和社会支持(100%vs 74.2%,p=0.01)。结论:我们的研究结果表明,败血症康复实践的采用情况各不相同。未来的工作需要了解为什么一些实践领域比其他领域更频繁地使用,以及如何促进实践的实施,特别是在情感支持等很少被采用的领域。
{"title":"A Multi-Hospital Survey of Current Practices for Supporting Recovery From Sepsis.","authors":"Rachel K Hechtman, Jennifer Cano, Taylor Whittington, Cainnear K Hogan, Sarah M Seelye, Jeremy B Sussman, Hallie C Prescott","doi":"10.1097/CCE.0000000000000926","DOIUrl":"10.1097/CCE.0000000000000926","url":null,"abstract":"<p><p>Sepsis survivors are at increased risk for morbidity and functional impairment. There are recommended practices to support recovery after sepsis, but it is unclear how often they are implemented. We sought to assess the current use of recovery-based practices across hospitals.</p><p><strong>Design: </strong>Electronic survey assessing the use of best practices for recovery from COVID-related and non-COVID-related sepsis. Questions included four-point Likert responses of \"never\" to \"always/nearly always.\"</p><p><strong>Setting: </strong>Twenty-six veterans affairs hospitals with the highest (<i>n</i> = 13) and lowest (<i>n</i> = 13) risk-adjusted 90-day sepsis survival.</p><p><strong>Subjects: </strong>Inpatient and outpatient clinician leaders.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>For each domain, we calculated the proportion of \"always/nearly always\" responses and mean Likert scores. We assessed for differences by hospital survival, COVID versus non-COVID sepsis, and sepsis case volume. Across eight domains of care, the proportion \"always/nearly always\" responses ranged from: 80.7% (social support) and 69.8% (medication management) to 22.5% (physical recovery and adaptation) and 0.0% (emotional support). Higher-survival hospitals more often performed screening for new symptoms/limitations (49.2% vs 35.1% \"always/nearly always,\" <i>p</i> = 0.02) compared with lower-survival hospitals. There was no difference in \"always/nearly always\" responses for COVID-related versus non-COVID-related sepsis, but small differences in mean Likert score in four domains: care coordination (3.34 vs 3.48, <i>p</i> = 0.01), medication management (3.59 vs 3.65, <i>p</i> = 0.04), screening for new symptoms/limitations (3.13 vs 3.20, <i>p</i> = 0.02), and anticipatory guidance and education (2.97 vs 2.84, <i>p</i> < 0.001). Lower case volume hospitals more often performed care coordination (72.7% vs 43.8% \"always/nearly always,\" <i>p</i> = 0.02), screening for new symptoms/limitations (60.6% vs 35.8%, <i>p</i> < 0.001), and social support (100% vs 74.2%, <i>p</i> = 0.01).</p><p><strong>Conclusions: </strong>Our findings show variable adoption of practices for sepsis recovery. Future work is needed to understand why some practice domains are employed more frequently than others, and how to facilitate practice implementation, particularly within rarely adopted domains such as emotional support.</p>","PeriodicalId":10759,"journal":{"name":"Critical Care Explorations","volume":"5 6","pages":"e0926"},"PeriodicalIF":0.0,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/12/cc9-5-e0926.PMC10456977.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10112163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Critical Care Explorations
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1